Search
Kava
go.drugbank.com/drugs/DB01322ApprovedInvestigationalNutraceuticalWithdrawnCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C19 InhibitorsQuinupristin
go.drugbank.com/drugs/DB01369ApprovedQuinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosom...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsGinkgo biloba
go.drugbank.com/drugs/DB01381ApprovedInvestigationalNutraceuticalGinkgo biloba extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of th...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP1A2 Inhibitors1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
go.drugbank.com/drugs/DB01562ExperimentalIllicit1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP) is a synthetic analogue of meperidine. It is sold as a "synthetic heroin."
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsXimelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnXimelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced th...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesOspemifene
go.drugbank.com/drugs/DB04938ApprovedOspemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
Synonyms: 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesIloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigationalIloperidone is a benzisoxazole and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. It is considered to be a second-generation antipsychotic drug with multiple receptor binding profile, although it shows...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBanoxantrone
go.drugbank.com/drugs/DB04975InvestigationalBanoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. It has been shown to work synergistically with fractionated radiation to significantly delay growth of t...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesPlitidepsin
go.drugbank.com/drugs/DB04977InvestigationalAplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatm...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesP-113D
go.drugbank.com/drugs/DB04987ExperimentalP-113D is a novel 12 amino-acid antimicrobial peptide drug derived from histatins, which are compounds found naturally in human saliva.